FDA Approves Kisunla (Donanemab) | Alzheimer's Association
CHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
New Drug Approved for Early Alzheimer’s - The New York Times
Jul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla | AP News
Jul 2, 2024 · The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.
FDA approves donanemab, now Kisunla, to treat early Alzheimer's
Jul 3, 2024 · The U.S. Food and Drug Administration (FDA) has approved Eli Lilly ‘s antibody therapy donanemab, now Kisunla, for certain adults with Alzheimer’s disease. Specifically, Kisunla is indicated for patients with early symptomatic Alzheimer’s — to include individuals with mild cognitive impairment or mild dementia, and confirmed evidence of ...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the …
Jul 2, 2024 · Kisunla™ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
FDA approves treatment for adults with Alzheimer’s disease
Jul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with...
FDA approves a second Alzheimer's drug that can modestly slow …
Jul 3, 2024 · The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to...
Alzhiemer's drug Kisunla from Eli Lilly gains FDA approval - USA TODAY
Jul 2, 2024 · Kisunla becomes the third amyloid-clearing Alzheimer's drug approved since 2021. Last year, the FDA approved Eisai and Biogen's drug Leqembi but required the drug to provide a warning about...
FDA approves 2nd Alzheimer's drug that can modestly slow …
Jul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22 percent more slowly in terms of...
FDA approves treatment for adults with Alzheimer’s disease
Jul 2, 2024 · The FDA granted this application Fast Track, Priority Review, and Breakthrough Therapy designations. The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.